A phase II randomized trial of sodium oligomannate in Alzheimer’s dementia

BACKGROUND: Sodium oligomannate (GV-971), a marine-derived oligosaccharide, is a novel agent that may improve cognition in AD patients. METHODS: The 24-week multicenter, randomized, double-blind, placebo parallel controlled clinical trial was conducted in AD in China between 24 October 2011 and 10 J...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Tao, Kuang, Weihong, Chen, Wei, Xu, Wenwei, Zhang, Liming, Li, Yingjie, Li, Hailin, Peng, Ying, Chen, Yangmei, Wang, Baojun, Xiao, Jinsong, Li, Honghua, Yan, Chuanzhu, Du, Yifeng, Tang, Mouni, He, Zhiyi, Chen, Haibo, Li, Wei, Lin, Hong, Shi, Shugui, Bi, Jianzhong, Zhou, Huadong, Cheng, Yan, Gao, Xiaoping, Guan, Yihui, Huang, Qiu, Chen, Kewei, Xin, Xianliang, Ding, Jian, Geng, Meiyu, Xiao, Shifu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2020
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7489025/
https://www.ncbi.nlm.nih.gov/pubmed/32928279
http://dx.doi.org/10.1186/s13195-020-00678-3

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7489025/
https://www.ncbi.nlm.nih.gov/pubmed/32928279
http://dx.doi.org/10.1186/s13195-020-00678-3

Ejemplares similares